RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Cangrelor Reduces Thrombotic Events among Patients Undergoing PCI
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 15
SP 24
OP 25
DO 10.1177/155989771315014
UL http://mdc.sagepub.com/content/13/15/24.1.abstract
AB This article presents pooled data from three clinical trials of cangrelor, an intravenous adenosine diphosphate-receptor antagonist in patients undergoing percutaneous coronary intervention (PCI) demonstrating significant reductions in thrombotic complications without an increase in major bleeding. The efficacy of the novel, investigational agent cangrelor has been evaluated in three randomized, double-blind, clinical trials against clopidogrel or placebo in patients during and after PCI: CHAMPION PHOENIX [Bhatt DL et al. N Engl J Med 2013]; CHAMPION PLATFORM [Bhatt DL et al. N Engl J Med 2009]; and CHAMPION PCI [Harrington RA et al. N Engl J Med 2009].